[go: up one dir, main page]

WO2012119605A1 - New disperse dye with potent anticancer activity - Google Patents

New disperse dye with potent anticancer activity Download PDF

Info

Publication number
WO2012119605A1
WO2012119605A1 PCT/EG2011/000002 EG2011000002W WO2012119605A1 WO 2012119605 A1 WO2012119605 A1 WO 2012119605A1 EG 2011000002 W EG2011000002 W EG 2011000002W WO 2012119605 A1 WO2012119605 A1 WO 2012119605A1
Authority
WO
WIPO (PCT)
Prior art keywords
disperse dye
anticancer activity
potent anticancer
new
new disperse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EG2011/000002
Other languages
French (fr)
Inventor
Yahya Ahmed Abdellhafeez Salem AKAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/EG2011/000002 priority Critical patent/WO2012119605A1/en
Publication of WO2012119605A1 publication Critical patent/WO2012119605A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • 2-cinnamyl-5,6,7,8-tetrahydro[l ]benzothieno[2,3-d )pyrimidine- 4(3H)-one is a yellow powder of new synthesized disperse dye which synthesized by reacting2-amino-4,5,6,7-tetrahydrobenzo[bjthiophene-3- carboxamide with cinnamaldehyde in presence of HCL(few drops) and filtered after 5 hours and filtrate is recrystallized from methanol then the powder is subjected to anticancer activity at the national cancer institute at different cell lines showing a potent anticancer activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New yellow disperse dye of 2-cinnamyl-5,6,7,8- tetrahydro[l]benzothieno[2,3-d]pyrimidine-4(3H)-one with a first medical application as anticancer showing potent activity against different cancer cell lines and low cytotoxicity to melanocytes (normal skin) which will be helpful in treatment of cancer specially melanoma due to dye stability on the skin.

Description

NEW DISPERSE DYE WITH POTENT
ANTICANCER ACTIVITY
Technical Field:
Treatment of cancer specially melanoma due to dye stability.
Background Art:
All disperse dyes was only used in polyester dyeing but no medical use.
Disclosure of Invention:
2-cinnamyl-5,6,7,8-tetrahydro[l ]benzothieno[2,3-d )pyrimidine- 4(3H)-one is a yellow powder of new synthesized disperse dye which synthesized by reacting2-amino-4,5,6,7-tetrahydrobenzo[bjthiophene-3- carboxamide with cinnamaldehyde in presence of HCL(few drops) and filtered after 5 hours and filtrate is recrystallized from methanol then the powder is subjected to anticancer activity at the national cancer institute at different cell lines showing a potent anticancer activity.

Claims

1. First medical application for disperse dye as anticancer.
2. New compound of yellow disperse dye.
PCT/EG2011/000002 2011-03-10 2011-03-10 New disperse dye with potent anticancer activity Ceased WO2012119605A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EG2011/000002 WO2012119605A1 (en) 2011-03-10 2011-03-10 New disperse dye with potent anticancer activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2011/000002 WO2012119605A1 (en) 2011-03-10 2011-03-10 New disperse dye with potent anticancer activity

Publications (1)

Publication Number Publication Date
WO2012119605A1 true WO2012119605A1 (en) 2012-09-13

Family

ID=44625918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2011/000002 Ceased WO2012119605A1 (en) 2011-03-10 2011-03-10 New disperse dye with potent anticancer activity

Country Status (1)

Country Link
WO (1) WO2012119605A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191537A1 (en) * 2015-05-28 2016-12-01 The Regents Of The University Of California Tubulin-binding compounds, compositions and uses related thereto

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032778A1 (en) * 2003-06-10 2005-02-10 Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use
US20050038053A1 (en) * 2003-06-10 2005-02-17 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032778A1 (en) * 2003-06-10 2005-02-10 Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use
US20050038053A1 (en) * 2003-06-10 2005-02-17 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PECH R ET AL: "UEBER THIENO-VERBINDUNGEN 7. MITTEILUNG: ZUR DARSTELLUNG VON 2-ARYLVINYL-3,4-DIHYDRO-4-OXOTHIENO Ä2,3-DÜPYRIMIDINEN//THIENO COMPOUNDS. PART 7. PREPARATION OF 2-(ARYLVINYL)-3,4-DIHYDRO-4-OXOTHI ENO Ä2,3-DÜPYRIMIDINES", DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 42, no. 2, 1 January 1987 (1987-01-01), pages 131, XP008047719, ISSN: 0031-7144 *
SHISHOO C J ET AL: "STUDIES ON THE SYNTHESIS OF 2-(2-ARYLVINYL)THIENO not 2,3-D 3/4 PYRIMIDINESAND 5-(2-ARYLVINYL)TRIAZOLOTHIENOL not 3,2-E 3/4 PYRIMIDINES", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 22, no. 3, 1 May 1985 (1985-05-01), pages 825 - 830, XP000983905, ISSN: 0022-152X, DOI: 10.1002/JHET.5570220343 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191537A1 (en) * 2015-05-28 2016-12-01 The Regents Of The University Of California Tubulin-binding compounds, compositions and uses related thereto
US10913750B2 (en) 2015-05-28 2021-02-09 The Regents Of The University Of California Tubulin-binding compounds, compositions and uses related thereto

Similar Documents

Publication Publication Date Title
WO2012013713A3 (en) Substituted imidazo[1,2-b]pyridazines
Xi et al. Structure-based design and synthesis of imidazo [1, 2-a] pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities
MX2014005184A (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2.
WO2014147525A3 (en) Perylenemonoimide and naphthalenemonoimide derivatives and their use in dye-sensitized solar cells
UY35115A (en) IMIDAZO [1,2-A] PIRIDINCARBOXAMIDS AMINOSUSTITUIDAS AND ITS USE
EP4566677A3 (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
NZ624068A (en) Fused tricyclic compounds as raf kinase inhibitors
PE20200725A1 (en) CRYSTALLINE FORMS OF THE ANDROGEN RECEPTOR MODULATOR: 4- [7- (6-CYANE-5-TRIFLUOROMETHYLPYRIDIN-3-IL) -8-OXO-6-THIOXO-5,7-DIAZAESPIRO [3,4] OCT-5-IL ] -2-FLUORO-N-METHYLBENZAMIDE) (APALUTAMIDE)
ECSP11011257A (en) TRIAZOL DERIVATIVES [4,3-B] PIRIDAZINE AND ITS USES FOR PROSTATE CANCER
PH12016500250B1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
MX2013001989A (en) Composition containing tetracyclic compound.
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
DOP2018000246A (en) 5,6,7,8–TETRAHYDRO[1,2,4]TRIAZOLO[4,3–A]PYRIDIN–3(2H)–ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1 SUBSTITUTED -C][1,2,4]TRIAZOL-3-ONES AND THEIR USE
WO2011077461A3 (en) Disperse azo dyes
Goodall et al. A tandem Diels–Alder/Mannich approach to the synthesis of AE and ABE ring analogues of Delphinium alkaloids
CO6460764A2 (en) [1,2,4] TRIAZOLO [4,3-B] PIRIDAZINAS AS LIGANDS OF THE ANDROGEN RECEIVER
WO2012020070A3 (en) Enhancement of the skin depigmentation
WO2012119605A1 (en) New disperse dye with potent anticancer activity
WO2013103925A3 (en) Liposomally encapsulated reduced glutathione for management of cancer with other uses and methods
WO2012021409A3 (en) Anthraquinone Analogs
GB201309925D0 (en) Preparation method for caspofungin analog
WO2011087712A3 (en) Tricyclic derivatives and their pharmaceutical use and compositions
AR098762A1 (en) 2- (4- (2- (1-ISOPROPIL-3-METHYL-1H-1,2,4-TRIAZOL-5-IL) -5,6-DIHYDROBENZO [F] IMIDAZO [1,2-D] [1,4] OXAZEPIN-9-IL) -1H-PIRAZOL-1-IL) -2-METHYLPROPANAMIDE, PRODUCTION METHODS, AND PHARMACEUTICAL USES OF THE SAME
WO2018161976A8 (en) Tetrapeptide propylene oxide derivative, preparation method therfor, and use thereof
WO2010121943A3 (en) Dyes for polymer coloration, their preparation and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11715160

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11715160

Country of ref document: EP

Kind code of ref document: A1